LIMN
Liminatus Pharma, Inc. Class A Common Stock·Healthcare
0.19
8.981%(−0.02)
Market ClosedLast Updated: — ET
52W L: $0.1652W H: $33.66
Liminatus Pharma, Inc. Class A Common Stock·Healthcare
Athira Pharma (NASDAQ: LONA - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk. Earnings and Valuation This table compares Athira
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation. Valuation and Earnings This table compares Liminatus
CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immune pathways and complement established immuno-oncology therapies.
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Valuation and Earnings This table compares Liminatus
CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company developing next-generation CD47-blockade therapies, today announced the pricing of its best-efforts public offering of 13,813,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per pre-funded warrant) and accompanying warrants. The warrants will have an exercise price of $0.29 per share, will be exercisable immediately upon issuance and will expire on the fifth anniversary of the original issuance date. The closing of the offering is expected to occur on or about February 18, 2026, subject to the satisfaction of customary closing conditions. Gross proceeds, before deducting placement agent fees and other estimated offering expenses, are expected to be approximately $4.0 million. The potential additional gross proceeds to the Company from the exercise of the warrants, if fully exercised on a cash basis, would be approximately $6.0 million. No assurance can be given that any warrants will be exercised.
